GenEditBio

Private

Hong KongHealthcare & Life Scienceshttps://geneditbio.com/

Last Round

Strategic

Sep 30, 2024

Total Funding Raised

$10.54M

Company Overview

GenEditBio is a biotechnology company that develops in vivo genome editing-based therapeutic solutions for genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

gene editingCRISPRin vivo gene editinggene therapydrug delivery systemgenetic disease therapylipid nanoparticleLNPCas nucleaserare disease treatmentprotein delivery vehiclePDVclinical stage biotechcurative treatmentAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GenEditBio Comps

Public and private peers based on sector, stage, and business model.

GenEditBio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GenEditBio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Strategic	Sep 30, 2024
Early Funding	Apr 4, 2024
Grant	Mar 1, 2024
Early Funding	May 25, 2022

View all Funding Rounds

Key People

Founding team and executive leadership

Tian Zhu

CEO & Co-Founder

Founding Team

GenEditBio Investors

Notable investors and investment history

GenEditBio investors
Investor	Rounds
FountainVest Partners	Early Funding
Hong Kong Science and Technology Park	Early Funding
Innovation and Technology Commission	Grant, Early Funding
Qiming Venture Partners	Grant, Early Funding
Gobi Partners GBA	Strategic

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 16, 2025
Grew 17% QoQ from 18 to 21 employees.
Sep 30, 2024
Led by Gobi Partners GBA.

View all signals

GenEditBio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

GenEditBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GenEditBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersHong Kong

Employee Range22

Year Founded2021

Last FundingSep 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.